[1]D'Antonio C, Passaro A, Gori B, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies[J]. Ther Adv Med Oncol. 2014,6(3):101-114.
[2]Yamagishi T, Fujimoto N, Miyamoto Y, et al. Brain metastases in malignant pleural mesothelioma[J]. Clin Exp Metastasis. 2016,33(3):231-237.
[3]苏加利,冯字清,朱道奇，等.全脑放疗联合吉非替尼治疗EGFR突变阳性肺腺癌脑转移[J].医学临床研究,2015,32(9):1764-1766.
[4]中国医师协会肿瘤医师分会,中国抗癌协会肿瘤临床化疗专业委员会.中国表皮生长因子受体基因突变和间变淋巴瘤激酶融合基因阳性非小细胞肺癌诊断治疗指南(2013版)[J].中华肿瘤杂志,2013,35(6):478-480.
[5]冯奉仪.实体瘤新的疗效评价标准(解读1.1版RECIST标准)[C].//第三届中国肿瘤内科大会论文集.2009:123-125.
[6]Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer[J]. J Clin Oncol. 2013,31(7):895-902.
[7]Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma[J]. Lung Cancer. 2013,82(2):282-287.
[8]Halasz LM, Uno H, Hughes M, et al. Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer[J]. Cancer. 2016 ,122(13):2091-2100. |
2017, Vol. 34 
